% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Trochopoulos:186458,
      author       = {A. G. X. Trochopoulos and Y. Ilieva and A. D. Kroumov and
                      L. L. Dimitrova and I. Pencheva-El Tibi and S. Philipov and
                      M. Berger$^*$ and H. M. Najdenski and K. Yoncheva and S. M.
                      Konstantinov and M. M. Zaharieva},
      title        = {{M}icellar {C}urcumin {S}ubstantially {I}ncreases the
                      {A}ntineoplastic {A}ctivity of the {A}lkylphosphocholine
                      {E}rufosine against {TWIST}1 {P}ositive {C}utaneous {T}
                      {C}ell {L}ymphoma {C}ell {L}ines.},
      journal      = {Pharmaceutics},
      volume       = {14},
      number       = {12},
      issn         = {1999-4923},
      address      = {Basel},
      publisher    = {MDPI},
      reportid     = {DKFZ-2022-03179},
      pages        = {2688},
      year         = {2022},
      abstract     = {Cutaneous T-cell lymphoma (CTCL) is a rare form of cancer
                      with local as well as systemic manifestations. Concomitant
                      bacterial infections increase morbidity and mortality rates
                      due to impaired skin barrier and immune deficiency. In the
                      current study, we demonstrated that the in vitro
                      anti-lymphoma potential of erufosine is diminished by TWIST1
                      expression and micellar curcumin substantially increases its
                      antineoplastic activity. Pharmacokinetic analysis showed
                      that the micellar curcumin (MCRM) used in our study was
                      characterized by low zeta potential, slow release of
                      curcumin, and fast cell membrane penetration. The
                      combination ratio 1:4 [erufosine:MCRM] achieved strong
                      synergism by inhibiting cell proliferation and
                      clonogenicity. The combined antiproliferative effects were
                      calculated using the symbolic mathematical software MAPLE
                      15. The synergistic combination strongly decreased the
                      expression of TWIST1 and protein kinase B/Akt as proven by
                      western blotting. Significant reductions in NF-κB
                      activation, induction of apoptosis, and altered glutathione
                      levels were demonstrated by corresponding assays. In
                      addition, the synergistic combination enhanced the
                      anti-staphylococcal activity and prevented biofilm
                      formation, as shown by crystal violet staining. Taken
                      together, the above results show that the development of
                      nanotechnological treatment modalities for CTCL, based on
                      rational drug combinations exhibiting parallel
                      antineoplastic and antibacterial effects, may prove
                      efficacious.},
      keywords     = {TWIST1 (Other) / curcumin (Other) / cutaneous T-cell
                      lymphoma (Other) / erufosine (Other) / nanotechnology
                      (Other) / synergy (Other)},
      cin          = {G401},
      ddc          = {610},
      cid          = {I:(DE-He78)G401-20160331},
      pnm          = {311 - Zellbiologie und Tumorbiologie (POF4-311)},
      pid          = {G:(DE-HGF)POF4-311},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:36559182},
      pmc          = {pmc:PMC9781439},
      doi          = {10.3390/pharmaceutics14122688},
      url          = {https://inrepo02.dkfz.de/record/186458},
}